TRVI on XNAS, Health Care, Trevi Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 25% in 12 months but Trevi lost $60.8M and burned $61.7M of free cash.
BadShort interest 12% of shares, up 5.3% in two weeks
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
expected around 16 Mar 2027 (an estimate: a year ago it reported on 17 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $21.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $21.5M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$21.5M
30 Jun 2026
–
-$17.8M
31 Mar 2026
–
-$13.2M
31 Dec 2025
–
-$8.3M
30 Sep 2025
–
-$11.8M
30 Jun 2025
–
-$12.3M
31 Mar 2025
–
-$10.3M
31 Dec 2024
–
-$11.4M
30 Sep 2024
–
-$13.2M
30 Jun 2024
–
-$12.4M
31 Mar 2024
–
-$10.9M
31 Dec 2023
–
-$7.8M
30 Sep 2023
–
-$7.7M
30 Jun 2023
–
-$7.1M
31 Mar 2023
–
-$6.4M
31 Dec 2022
–
-$5.5M
30 Sep 2022
–
-$8.3M
30 Jun 2022
–
-$8.1M
31 Mar 2022
–
-$7.3M
31 Dec 2021
–
-$8.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$60.8M
-$45.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.39
-$0.37
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-24.7%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$61.7M
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$299.4M
$194.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$299.4M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$2.12
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
6.3
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$596K
bought $0, sold $596K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+3.3%
222 13F filers vs 215
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
151.2M shares held by 13F filers (30 Sep 2026) of 142.6M outstanding (31 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
12%
16.9M shares sold short (30 Oct 2026) of 142.6M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.1
16.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+5.3%
16.0M shares sold short in the report before, 16.9M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
28%
28% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
6
6 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
6.0×
6 articles in the last 7 days; its usual week has 1.
Price $13.35 on 20 Nov 2026, +25% over 12 months (12-month range $9.99 to $19.50)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $596K in the last 12 months (the 12 months before: -$601K).Capital spending per quarter. Capital spending $25K in the latest quarter, +108% on a year earlier.Institutional holders (13F filers). 222 13F filers reported holding it in the latest 13F quarter, +39% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2022: $116K; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $57K; public on 12 May 2023
Quarter ended 30 Jun 2023: $40K; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $18K; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $22K, -81% on a year earlier; public on 21 Mar 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $7K, -68% on a year earlier; public on 19 Mar 2025
Quarter ended 30 Sep 2025: $12K; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 18 Mar 2026
Quarter ended 31 Mar 2026: $102K; public on 6 May 2026
Quarter ended 30 Jun 2026: $124K; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $25K, +108% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 17; public on 14 Feb 2022
31 Mar 2022 report: 22; public on 16 May 2022
30 Jun 2022 report: 32; public on 15 Aug 2022
30 Sep 2022 report: 38; public on 14 Nov 2022
31 Dec 2022 report: 36; public on 14 Feb 2023
31 Mar 2023 report: 35; public on 15 May 2023
30 Jun 2023 report: 48; public on 14 Aug 2023
30 Sep 2023 report: 51; public on 14 Nov 2023
31 Dec 2023 report: 60; public on 14 Feb 2024
31 Mar 2024 report: 78; public on 15 May 2024
30 Jun 2024 report: 75; public on 14 Aug 2024
30 Sep 2024 report: 89; public on 14 Nov 2024
31 Dec 2024 report: 106; public on 14 Feb 2025
31 Mar 2025 report: 134; public on 15 May 2025
30 Jun 2025 report: 149; public on 14 Aug 2025
30 Sep 2025 report: 160; public on 14 Nov 2025
31 Dec 2025 report: 178; public on 17 Feb 2026
31 Mar 2026 report: 195; public on 15 May 2026
30 Jun 2026 report: 215; public on 14 Aug 2026
30 Sep 2026 report: 222; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $596K (17 Sep 2026), 14× its normal reading; higher than 93% of its own history.
Two or more unrelated kinds of records unusual within 30 days
14 Apr 2022confirmed
Confirmed across sources Insiders and Short interest and volume
Trevi Therapeutics(TRVI): had 3 insiders buy $11.8M of its shares on the open market within 30 days (3 filings), while it had 549K shares sold short in the 14 Apr 2022 report, 6.2× the same report last year. Two unrelated kinds of activity within 49 days.
Short interest and volume: Short interest spike, became public on 10 Mar 2022
Short interest and volume: Short interest spike, became public on 25 Mar 2022
Insiders: Clustered insider buying, became public on 14 Apr 2022
Short interest and volume: Short interest spike, became public on 27 Apr 2022
The 14 Apr 2022 report against the 24 reports before it.
this reportearliernormal: 88KSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 10 Mar 2022
Trevi Therapeutics had 591K shares sold short in the 28 Feb 2022 report, 11× the same report last year.
This period
591K (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
87K
Typical spread (median absolute deviation)
14K
How far from its usual level
+10.1
Same report last year
54K
History used
1,020 days
the 28 Feb 2022 report24 earlier reportsnormal: 87K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2022
Trevi Therapeutics had 832K shares sold short in the 15 Mar 2022 report, 6.6× the same report last year.
This period
832K (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
14K
How far from its usual level
+14.9
Same report last year
126K
History used
1,035 days
the 15 Mar 2022 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Insiders: Clustered insider buying became public on 14 Apr 2022
Trevi Therapeutics had 3 insiders buy $11.8M of its shares on the open market within 30 days (3 filings).
Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$11.8M
Window
15 Mar 2022 to 14 Apr 2022
BASKETT FOREST (ten percent owner) bought 2,631,578 shares of TRVI ($5.0M)dated 13 Apr 2022, public 14 Apr 2022
Behbahani Ali (ten percent owner) bought 3,580,526 shares of TRVI ($1.8M)dated 13 Apr 2022, public 14 Apr 2022
NEA 16 GP, LLC (ten percent owner) and 2 other(s) bought 2,631,578 shares of TRVI ($5.0M)dated 13 Apr 2022, public 14 Apr 2022
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 27 Apr 2022
Trevi Therapeutics had 549K shares sold short in the 14 Apr 2022 report, 6.2× the same report last year.
This period
549K (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
15K
How far from its usual level
+9.2
Same report last year
89K
History used
1,065 days
the 14 Apr 2022 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
5 Dec 2025Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
had 7.0M shares sold short in the 30 May 2025 report, 8.3× the same report last year.
Same report last year: 850K; its normal report is 1.7M.
See the evidence
This period
7.0M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
831K
How far from its usual level
+4.3
Same report last year
850K
History used
2,207 days
the 30 May 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.9M shares sold short in the 15 May 2025 report, 7.0× the same report last year.
Same report last year: 986K; its normal report is 1.6M.
See the evidence
This period
6.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
676K
How far from its usual level
+5.2
Same report last year
986K
History used
2,192 days
the 15 May 2025 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.0M shares sold short in the 30 Apr 2025 report, 6.6× the same report last year.
Same report last year: 1.1M; its normal report is 1.5M.
See the evidence
This period
7.0M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
565K
How far from its usual level
+6.5
Same report last year
1.1M
History used
2,177 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.9M shares sold short in the 15 Apr 2025 report, 6.6× the same report last year.
Same report last year: 898K; its normal report is 1.5M.
See the evidence
This period
5.9M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
542K
How far from its usual level
+5.5
Same report last year
898K
History used
2,162 days
the 15 Apr 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.5M shares sold short in the 31 Mar 2025 report, 5.3× the same report last year.
Same report last year: 1.0M; its normal report is 1.5M.
See the evidence
This period
5.5M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
487K
How far from its usual level
+5.5
Same report last year
1.0M
History used
2,147 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.7M shares sold short in the 14 Mar 2025 report, 4.4× the same report last year.
Same report last year: 1.1M; its normal report is 1.5M.
See the evidence
This period
4.7M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
405K
How far from its usual level
+5.4
Same report last year
1.1M
History used
2,130 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.8M shares sold short in the 28 Feb 2025 report, 3.1× the same report last year.
Same report last year: 1.2M; its normal report is 1.4M.
See the evidence
This period
3.8M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
349K
How far from its usual level
+4.6
Same report last year
1.2M
History used
2,116 days
the 28 Feb 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.3M shares sold short in the 14 Feb 2025 report, 3.6× the same report last year.
Same report last year: 1.2M; its normal report is 1.3M.
See the evidence
This period
4.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
294K
How far from its usual level
+6.9
Same report last year
1.2M
History used
2,102 days
the 14 Feb 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.6M shares sold short in the 31 Jan 2025 report, 3.3× the same report last year.
Same report last year: 1.4M; its normal report is 1.3M.
See the evidence
This period
4.6M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
273K
How far from its usual level
+8.0
Same report last year
1.4M
History used
2,088 days
the 31 Jan 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.1M shares sold short in the 15 Jan 2025 report, 3.3× the same report last year.
Same report last year: 1.2M; its normal report is 1.3M.
See the evidence
This period
4.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
232K
How far from its usual level
+8.3
Same report last year
1.2M
History used
2,072 days
the 15 Jan 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 31 Dec 2024 report, 3.3× the same report last year.
Same report last year: 1.2M; its normal report is 1.3M.
See the evidence
This period
3.9M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
226K
How far from its usual level
+7.8
Same report last year
1.2M
History used
2,057 days
the 31 Dec 2024 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.7M shares sold short in the 13 Dec 2024 report, 4.6× the same report last year.
Same report last year: 1.0M; its normal report is 1.2M.
See the evidence
This period
4.7M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
209K
How far from its usual level
+11.0
Same report last year
1.0M
History used
2,039 days
the 13 Dec 2024 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 30 Nov 2023 report, 4.5× the same report last year.
Same report last year: 243K; its normal report is 245K.
See the evidence
This period
1.1M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
245K
Typical spread (median absolute deviation)
162K
How far from its usual level
+3.5
Same report last year
243K
History used
1,660 days
the 30 Nov 2023 report24 earlier reportsnormal: 245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 15 Nov 2023 report, 3.9× the same report last year.
Same report last year: 290K; its normal report is 245K.
See the evidence
This period
1.1M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
245K
Typical spread (median absolute deviation)
153K
How far from its usual level
+3.9
Same report last year
290K
History used
1,645 days
the 15 Nov 2023 report24 earlier reportsnormal: 245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Oct 2023 report, 3.9× the same report last year.
Same report last year: 296K; its normal report is 245K.
See the evidence
This period
1.2M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
245K
Typical spread (median absolute deviation)
150K
How far from its usual level
+4.1
Same report last year
296K
History used
1,630 days
the 31 Oct 2023 report24 earlier reportsnormal: 245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 13 Oct 2023 report, 3.0× the same report last year.
Same report last year: 405K; its normal report is 245K.
See the evidence
This period
1.2M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
245K
Typical spread (median absolute deviation)
150K
How far from its usual level
+4.4
Same report last year
405K
History used
1,612 days
the 13 Oct 2023 report24 earlier reportsnormal: 245K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 29 Sep 2023 report, 11× the same report last year.
Same report last year: 111K; its normal report is 243K.
See the evidence
This period
1.3M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
243K
Typical spread (median absolute deviation)
139K
How far from its usual level
+4.9
Same report last year
111K
History used
1,598 days
the 29 Sep 2023 report24 earlier reportsnormal: 243K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 15 Sep 2023 report, 13× the same report last year.
Same report last year: 99K; its normal report is 235K.
See the evidence
This period
1.3M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
235K
Typical spread (median absolute deviation)
130K
How far from its usual level
+5.6
Same report last year
99K
History used
1,584 days
the 15 Sep 2023 report24 earlier reportsnormal: 235K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 31 Aug 2023 report, 12× the same report last year.
Same report last year: 110K; its normal report is 215K.
See the evidence
This period
1.3M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
215K
Typical spread (median absolute deviation)
104K
How far from its usual level
+7.1
Same report last year
110K
History used
1,569 days
the 31 Aug 2023 report24 earlier reportsnormal: 215K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 15 Aug 2023 report, 12× the same report last year.
Same report last year: 112K; its normal report is 188K.
See the evidence
This period
1.4M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
188K
Typical spread (median absolute deviation)
91K
How far from its usual level
+8.8
Same report last year
112K
History used
1,553 days
the 15 Aug 2023 report24 earlier reportsnormal: 188K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 31 Jul 2023 report, 9.5× the same report last year.
Same report last year: 139K; its normal report is 167K.
See the evidence
This period
1.3M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
167K
Typical spread (median absolute deviation)
74K
How far from its usual level
+10.6
Same report last year
139K
History used
1,538 days
the 31 Jul 2023 report24 earlier reportsnormal: 167K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 14 Jul 2023 report, 6.6× the same report last year.
Same report last year: 198K; its normal report is 167K.
See the evidence
This period
1.3M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
167K
Typical spread (median absolute deviation)
72K
How far from its usual level
+10.7
Same report last year
198K
History used
1,521 days
the 14 Jul 2023 report24 earlier reportsnormal: 167K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 30 Jun 2023 report, 13× the same report last year.
Same report last year: 99K; its normal report is 149K.
See the evidence
This period
1.3M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
149K
Typical spread (median absolute deviation)
54K
How far from its usual level
+14.8
Same report last year
99K
History used
1,507 days
the 30 Jun 2023 report24 earlier reportsnormal: 149K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 549K shares sold short in the 14 Apr 2022 report, 6.2× the same report last year.
Same report last year: 89K; its normal report is 88K.
See the evidence
This period
549K (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
15K
How far from its usual level
+9.2
Same report last year
89K
History used
1,065 days
the 14 Apr 2022 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3 insiders buy $11.8M of its shares on the open market within 30 days (3 filings), while it had 549K shares sold short in the 14 Apr 2022 report, 6.2× the same report last year. Two unrelated kinds of activity within 49 days.
See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 10 Mar 2022
Trevi Therapeutics had 591K shares sold short in the 28 Feb 2022 report, 11× the same report last year.
This period
591K (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
87K
Typical spread (median absolute deviation)
14K
How far from its usual level
+10.1
Same report last year
54K
History used
1,020 days
the 28 Feb 2022 report24 earlier reportsnormal: 87K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2022
Trevi Therapeutics had 832K shares sold short in the 15 Mar 2022 report, 6.6× the same report last year.
This period
832K (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
14K
How far from its usual level
+14.9
Same report last year
126K
History used
1,035 days
the 15 Mar 2022 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Insiders: Clustered insider buying became public on 14 Apr 2022
Trevi Therapeutics had 3 insiders buy $11.8M of its shares on the open market within 30 days (3 filings).
Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$11.8M
Window
15 Mar 2022 to 14 Apr 2022
BASKETT FOREST (ten percent owner) bought 2,631,578 shares of TRVI ($5.0M)dated 13 Apr 2022, public 14 Apr 2022
Behbahani Ali (ten percent owner) bought 3,580,526 shares of TRVI ($1.8M)dated 13 Apr 2022, public 14 Apr 2022
NEA 16 GP, LLC (ten percent owner) and 2 other(s) bought 2,631,578 shares of TRVI ($5.0M)dated 13 Apr 2022, public 14 Apr 2022
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 27 Apr 2022
Trevi Therapeutics had 549K shares sold short in the 14 Apr 2022 report, 6.2× the same report last year.
This period
549K (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
15K
How far from its usual level
+9.2
Same report last year
89K
History used
1,065 days
the 14 Apr 2022 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Apr 2022Insiders change
had 3 insiders buy $11.8M of its shares on the open market within 30 days (3 filings).
Who bought: Baskett Forest, Behbahani Ali.
See the evidence (3 source records)
Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$11.8M
Window
15 Mar 2022 to 14 Apr 2022
BASKETT FOREST (ten percent owner) bought 2,631,578 shares of TRVI ($5.0M)dated 13 Apr 2022, public 14 Apr 2022
Behbahani Ali (ten percent owner) bought 3,580,526 shares of TRVI ($1.8M)dated 13 Apr 2022, public 14 Apr 2022
NEA 16 GP, LLC (ten percent owner) and 2 other(s) bought 2,631,578 shares of TRVI ($5.0M)dated 13 Apr 2022, public 14 Apr 2022
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 101 entries; narrow the window or the kind of data to see older ones.
Not listed: 135 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001563880
Ticker
TRVI
Domain
trevitherapeutics.com
Hq location
CT|NEW HAVEN|06510 (1 unverified)
Name
Trevi Therapeutics, Inc.
SEC Form 13F institutional holdings270 data points30 Jun 2019 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)123 records24 Jul 2017 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)436 data points31 Dec 2017 to 31 Oct 2026
SEC Form 4 insider transactions77 records, 120 data points13 May 2019 to 17 Sep 2026
FINRA short interest (twice monthly)536 data points15 May 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3762 data points7 May 2019 to 20 Nov 2026